Rifampicin

Generic Name: Rifampicin

Brand Names: Isonarif, Rifadin, Rifamate, Rifater, Rofact

Drug Type: Small Molecule

Chemical Formula: C_₄₃H_₅₈N_₄O_₁₂

CAS Number: 13292-46-1

Unique Ingredient Identifier: VJT6J7R4TR

Background: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)

Indication: Rifampin is indicated for the treatment of tuberculosis and tuberculosis-related mycobacterial infections. In combination with pyrazinamide and isoniazid, it is used in the initial phase of the short-course treatment of pulmonary tuberculosis.

Associated Conditions: Cholestatic pruritus, MRSA Infections, Prosthetic Joint Infections, Asymptomatic Neisseria meningitidis carrier of the nasopharynx, Initial phase Tuberculosis, Late phase Tuberculosis

Associated Therapies: Antibacterial therapy

Clinical Trials

Drug-drug Interaction Study of SPH3127

Phase 1

Completed

Conditions: Drug Drug Interaction

Interventions: Drug: SPH3127 tablet
Drug: Itraconazole
Drug: Rifampin

First Posted Date: 2022-05-03

Last Posted Date: 2022-07-29

Lead Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd

Target Recruit Count: 40

Registration Number: NCT05359055

Locations: 🇨🇳
West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China

A Study of AB-106 in Chinese Healthy Adult Men Evaluated the Effects of Itraconazole and Rifampicin on AB-106 PK

Phase 1

Completed

Conditions: Solid Tumor

Interventions: Drug: AB-106, Itraconazole
Drug: AB-106, Rifampicin

First Posted Date: 2022-05-03

Last Posted Date: 2024-11-21

Lead Sponsor: Nuvation Bio Inc.

Target Recruit Count: 56

Registration Number: NCT05357820

Locations: 🇨🇳
Xuanwu Hospital of Capital Medical University, Beijing, China

A Study of Effects of Itraconazole and Rifampin on Selpercatinib (LY3527723) in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Selpercatinib
Drug: Itraconazole
Drug: Rifampin

First Posted Date: 2022-04-21

Last Posted Date: 2022-04-21

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 24

Registration Number: NCT05338489

Locations: 🇺🇸
Celerion, Tempe, Arizona, United States

PK Study to Assess Drug-drug Interaction Between Sitravatinib and a P-gp Inducer and an Inhibitor.

Phase 1

Completed

Conditions: Healthy Adults

Interventions: Drug: Sitravatinib 50 mg
Drug: Sitravatinib 100 mg
Drug: Itraconazole
Drug: Rifampin

First Posted Date: 2022-02-24

Last Posted Date: 2024-05-08

Lead Sponsor: Mirati Therapeutics Inc.

Target Recruit Count: 36

Registration Number: NCT05255276

Locations: 🇺🇸
Labcorp Drug Development Clinical Research Unit, Dallas, Texas, United States

Beta-Lactam Containing Regimen for the Shortening of Buruli Ulcer Disease Therapy

Phase 2

Recruiting

Conditions: Buruli Ulcer

First Posted Date: 2021-12-27

Last Posted Date: 2024-05-16

Lead Sponsor: Fundacion Agencia Aragonesa para la Investigacion y Desarrollo (ARAID)

Target Recruit Count: 140

Registration Number: NCT05169554

Locations: 🇧🇯
Centre de Dépistage et de Traitement de l'Ulcère de Buruli (CDTUB) (Centers for Detection and Treatment of Buruli ulcer), Lalo, Lalo, Benin
🇧🇯
Centre de Dépistage et de Traitement de l'Ulcère de Buruli (CDTUB) (Centers for Detection and Treatment of Buruli ulcer), Pobè, Pobè, Benin
🇧🇯
Centre de Dépistage et de Traitement de l'Ulcère de Buruli (CDTUB) (Centers for Detection and Treatment of Buruli ulcer), Allada, Allada, Benin